Protext Mobility, Inc. announced that it has signed an agreement with the Centre International de Developpment Pharmaceutique (CIDP) to conduct a human clinical trial with its product Phytofare Catechin Complex, in the country of Mauritius. The study is titled Clinical Trial on Humans to determine the efficacy of Phytofare for lowering HbA1C levels in II Diabetes patients. When glucose builds up in a person's blood, it binds to the hemoglobin in red blood cells. The HbA1C test measures how much glucose is bound over a 2-3 month period to determine average plasma glucose concentration. The objective of the study is to determine the efficacy of Phytofare® Catechin Complex for improving the levels of hypoglycemia in people with diabetes as emphasized in the American Diabetes Association's new 2017 Standards of Medical Care in Diabetes. The company expects to begin phase-one with a bioavailability study this month with CIC Cynologies to confirm the human clinical study dosage of Phytofare Catechin Complex. Results are anticipated for release in June; then followed by the implementation of the Type-II diabetes human clinical trial in the second half of 2017, to be undertaken by CIDP.